Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index; 39 of the 79 sources its claims cite were checked for support.

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease

Open access
Wang, Xiaoqi, Huang, Weijie, Su, Li, Xing, Yue, Jessen, Frank, Sun, Yu, Shu, Ni, Han, Ying · 2020 · Molecular Neurodegeneration

Abstract

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility.

Overview

CoChat Summary

TL;DR

This is a narrative review of neuroimaging studies in subjective cognitive decline (SCD) related to Alzheimer’s disease (AD), summarizing molecular, structural, and functional imaging findings. The authors conclude that SCD shows preferential vulnerability in AD-signature regions and that multimodal, longitudinal imaging is needed to clarify heterogeneous findings and improve early detection.

Key findings

  • The review included 114 studies published from January 1994 to September 2019, identified through PubMed and ScienceDirect.
  • PET studies in SCD reported amyloid pathology prevalence of 12%–43% in a meta-analysis; several studies found higher amyloid positivity than healthy controls and associations between amyloid burden and SCD severity, but results were inconsistent.
  • Structural MRI/DTI findings in SCD often showed decreased hippocampal volume, thinner entorhinal/temporal-parietal cortex, and white-matter microstructural disruption; some longitudinal work reported an annual hippocampal decrease of 1.9%.
  • Functional imaging frequently implicated the default mode network (DMN) and AD-signature regions, with rs-fMRI, task fMRI, ASL, and EEG/MEG studies showing mixed but recurring abnormalities in connectivity, activation, perfusion, and oscillatory activity.

Methods

  • Narrative review design focused on neuroimaging changes in SCD related to AD across PET, MRI, fMRI, ASL, EEG, and MEG.
  • Literature search of PubMed and ScienceDirect for English full-text original studies published January 1994–September 2019; included studies required SCD with normal standard neuropsychological performance and no other medical/psychiatric causes.
  • The authors synthesized findings qualitatively by imaging modality and discussed heterogeneity, multimodal studies, longitudinal work, and artificial intelligence approaches.

Limitations

  • The paper states that longitudinal research is still limited, and most studies are cross-sectional, which does not capture individual trajectories or establish causality.
  • The review notes that findings are heterogeneous and inconsistent because of differences in SCD definitions, cohort demographics, and acquisition/quantification methods.
  • Evident limitation: this is a review, so it does not report new primary participant data or a formal meta-analysis in the provided text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13024-020-00395-3

Cites

215 of 216 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart of the literature screening process and results. Abbreviations: SCD=subjective cognitive decline; CVD=cerebrovascular disease; PD=Parkinson’s disease; DLB=dementia with Lewy body; MCI=mild cognitive impairment; AD=Alzheimer’s disease
Figure 1 Flowchart of the literature screening process and results. Abbreviations: SCD=subjective cognitive decline; CVD=cerebrovascular disease; PD=Parkinson’s disease; DLB=dementia with Lewy body; MCI=mild cognitive impairment; AD=Alzheimer’s diseaseCC BY · PubMed Central
Fig. 2 Multimodal imaging signature of SCD. The consistent results were collected from the articles included in this review to provide a comprehensive summary of common neuroimaging changes in SCD. a SCD individuals exhibit a pattern of amyloid accumulation within the medial prefrontal, cingulum and precuneus cortex, which are early sites of vulnerability in MCI and dementia due to AD. b The medial temporal lobe is frequently characterized by hypometabolism, whereas other studies have reported a strong association between SCD and hypometabolism within the precuneus. c Individuals with SCD showed decreased hippocampal volume and thinner entorhinal cortex than healthy controls. d The abnormal FC between the posterior DMN and other regions are frequently reported in resting-state fMRI studies. e DTI studies have reported decreased FA in hippocampal and parahippocampal white matter in SCD individuals. Abbreviations: SCD = Subjective cognitive decline; MCI = Mild cognitive impairment; AD = Alzheimer’s disease; DTI = Diffusion tensor imaging; DMN = Default mode network; fMRI = Functional MRI; FC=Functional connectivity
Fig. 2 Multimodal imaging signature of SCD. The consistent results were collected from the articles included in this review to provide a comprehensive summary of common neuroimaging changes in SCD. a SCD individuals exhibit a pattern of amyloid accumulation within the medial prefrontal, cingulum and precuneus cortex, which are early sites of vulnerability in MCI and dementia due to AD. b The medial temporal lobe is frequently characterized by hypometabolism, whereas other studies have reported a strong association between SCD and hypometabolism within the precuneus. c Individuals with SCD showed decreased hippocampal volume and thinner entorhinal cortex than healthy controls. d The abnormal FC between the posterior DMN and other regions are frequently reported in resting-state fMRI studies. e DTI studies have reported decreased FA in hippocampal and parahippocampal white matter in SCD individuals. Abbreviations: SCD = Subjective cognitive decline; MCI = Mild cognitive impairment; AD = Alzheimer’s disease; DTI = Diffusion tensor imaging; DMN = Default mode network; fMRI = Functional MRI; FC=Functional connectivityCC BY · PubMed Central

Verification

Claims the paper makes

24 Valid · 1 Not valid · 14 Not checked · 50 Own results and interpretations

47 more claims · 9 with their cited sources checked

Create a free account to see all 89 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 5
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 214 references

Cited by

See all 266

Metadata

Authors
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y.
Affiliations
  • Capital Medical University (CN)
  • Beijing Normal University (CN)
  • Southwest University (CN)
  • University of Nottingham (GB)
  • University of Cologne (DE)
Corresponding author
  • Sun, Yu
  • Shu, Ni
  • Han, Ying
Venue
Molecular Neurodegeneration
Published
2020-09-22
Volume
15
Issue
1
Pages
55-55
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3088567733
Cited by
265
References
214
Citations by year
2026: 32 · 2025: 62 · 2024: 45 · 2023: 49 · 2022: 33 · 2021: 43 · 2020: 1
FWCI
5.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • DZNE Pub (publishedVersion, other-oa)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
  • Apollo
Funders
  • National Key Research and Development Program of China (2016YFC1306300, 2018YFC1312001)
  • National Natural Science Foundation of China (61633018, 81671761, 81871425)
  • Beijing Municipal Commission of Health and Family Planning (PXM2020_026283_000002)
  • Fundamental Research Funds for the Central University (2017XTCX04)
  • Beijing Nature Science Foundation (7161009)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
Keywords
subjective cognitive decline, preclinical Alzheimer's disease, neuroimaging biomarkers, brain structural changes, brain connectivity, APOE ε4, mild cognitive impairment, dementia, early detection of Alzheimer's disease, age as risk factor
MeSH terms
Alzheimer Disease, Female, Humans, Male, Early Diagnosis, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13024-020-00395-3
The paper
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020). Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00395-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.